Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma

Published:2022-12-19 Issue:1 Volume:6 Page:
ISSN:2573-8348
Container-title:Cancer Reports
language:en
Short-container-title:Cancer Reports

Author:

Yang Shuwen¹^ORCID,Ji Dongmei²,Xue Fen³,Chen Tongzhen⁴,Wang Yu¹^ORCID,Ji Qinhai¹

Affiliation:

1. Department of Head and Neck Surgery Fudan University Shanghai Cancer Center Shanghai China

2. Medical Oncology Fudan University Shanghai Cancer Center Shanghai China

3. Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China

4. Pathology Fudan University Shanghai Cancer Center Shanghai China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cnr2.1770

Reference28 articles.

1. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib inBRAFV600E-Mutated Anaplastic Thyroid Carcinoma

2. Targeted therapy: A new hope for thyroid carcinomas

3. BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

4. BRAF mutation in papillary thyroid carcinoma: Predictive value for long-term prognosis and radioiodine sensitivity

5. Update on Anaplastic Thyroid Carcinoma: Morphological, Molecular, and Genetic Features of the Most Aggressive Thyroid Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of immunotherapy against anaplastic thyroid cancer;Frontiers in Oncology;2024-03-26

2. Famitinib;Reactions Weekly;2023-11-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3